Estradiol/levonorgestrel (E2/LNG), sold under brand name Climara Pro, is a combination of estradiol (E2) and levonorgestrel (LNG) which is used in menopausal hormone therapy.[1][2][3] It is a 22-cm2 transdermal patch containing 4.4 mg estradiol and 1.39 mg levonorgestrel and delivers 45 μg/day estradiol and 15 μg/day levonorgestrel.[1][4] E2/LNG was approved for medical use in the United States in 2003.[5]
| Combination of | |
|---|---|
| Estradiol | Estrogen |
| Levonorgestrel | Progestogen |
| Clinical data | |
| Trade names | Climara Pro |
| Other names | E2/LNG |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
See also
editReferences
edit- ^ a b "Climara Pro Prescribing Information" (PDF). U.S. Food and Drug Administration.
- ^ Shulman LP (December 2004). "17Beta-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman". Expert Opinion on Pharmacotherapy. 5 (12): 2559–66. doi:10.1517/14656566.5.12.2559. PMID 15571472. S2CID 24659973.
- ^ Dando TM, Perry CM (2004). "17 beta-estradiol/levonorgestrel transdermal system". Treatments in Endocrinology. 3 (5): 319–24. doi:10.2165/00024677-200403050-00005. PMID 15330679. S2CID 72554239.
- ^ Wiedersberg S, Guy RH (September 2014). "Transdermal drug delivery: 30+ years of war and still fighting!" (PDF). Journal of Controlled Release. 190: 150–6. doi:10.1016/j.jconrel.2014.05.022. PMID 24852092. S2CID 13842061.
- ^ Traynor K (February 2004). "New drug and biological product approvals, 2003". American Journal of Health-System Pharmacy. 61 (4): 338–340. doi:10.1093/ajhp/61.4.338. PMID 15011760.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |